Hints and tips:
Related Special Reports
...and Co Q4, Enel FY, ICE Q4, Infineon Technologies Q3, ING Q4, Merck & Co Q4, Nintendo Q3, Nokia FY, Norton LifeLock Q3, OMV Q4, Prudential Financial Q4, Ralph Lauren Q3, Roche FY, Shell Q4, Skanska FY, Takeda...
...“We have been operating in stealth mode until now,” said Tristan Edwards, an Australian investment professional who founded the Boston-based company in 2016 with David Sinclair, professor of genetics at...
...Harf hired David Kamenetzky, formerly of Anheuser-Busch InBev, to help represent the interests of its main backer, Germany’s billionaire Reimann family....
...“The investment required is too large for any company,” said Christophe Weber, chief executive of Takeda, the Japanese drugs and vaccines company. “Society will have to finance this huge investment....
...In March, Tsunekazu Takeda, the head of Japan’s Olympic Committee, stood down from his role....
...Mr Takeda said on Friday that he had not been indicted and that there had been no improper actions related to the Olympic bid....
...Additional reporting by David Keohane in Paris....
...Unusually, Recursion is trying to make its own drugs for rare diseases, as well as partnering with large pharmaceutical companies Takeda and Sanofi on other rare diseases, and hoping to sign deals with pharma...
...Investors are upbeat about the company’s acquisition of a business previously owned by Japanese rival Takeda, and a touted merger of three Celltrion affiliates. Song Jung-a 64....
...executive education at Harvard Medical School, with other companies such as US conglomerate General Electric, cloud computing platform Athenahealth, also of the US, and Japanese pharmaceutical company Takeda...
...In an interview with the Financial Times, Mr Weber said Takeda had evaluated the threats before arriving at a £46bn valuation for Shire....
...David Oskandy, general counsel at technology consulting company Avanade, says: “A general counsel under legal or regulatory or public scrutiny needs to bring broader thinking and capabilities to bear beyond...
...The top five funders are Pfizer, Takeda, Novartis, AbbVie, and Lilly....
...DDF is part of the health legacy of former UK prime minister David Cameron, who made fighting dementia a priority at the G8 meeting that he chaired in 2013....
...After many false starts over the past decade, David Gross-Loh, the co-head of Bain’s Asia business, says “allergy to private equity has more or less gone”....
...David Roper, one of the founders of the UK’s Melrose Industries, announced on Thursday that he would retire at the end of May next year. His nickname is The Grinder. More here....
...(WSJ) News round-up Takeda wins shareholder approval for £46bn Shire acquisition (FT) Drug dealin’: advisers work for $1bn payday on Takeda-Shire deal (DD Flashback) Mike Bloomberg says he'd try to sell...
...two-thirds shareholder approval to close the Japanese group’s £46bn bid for Shire, write Kana Inagaki in Tokyo and David Crow in New York....
...David Zweig, a China specialist based in Hong Kong, writes that the worsening trade war between Washington and Beijing should be seen as a skirmish in a wider battle for global technological hegemony....
...London legal: another Kirkland poach rattles magic circle It was just over a year ago that US law firm Kirkland & Ellis stunned legal London with the hire of private equity supremo David Higgins from Freshfields...
...David Folkerts-Landau writes that Europe must cut a grand bargain with Italy....
...Last week, Japan’s Takeda Pharmaceutical reached a preliminary agreement to buy Irish drugmaker Shire for about £46bn in a deal that bankers predicted was a portent of things to come....
...David Higgins, partner at Kirkland & Ellis, said: “Some uncertainty in the markets may also help PE funds as they search for value opportunities....
...Rage against the deal: Takeda/Shire The dissident shareholders of Japan’s Takeda are on the move....
...“Takeda is one of the most conservative companies out there in the space when it comes to M&A, and personally I do not think Takeda will go through with this,” said Panmure Gordon analyst David Cox....
International Edition